{"id":{"repo_id":"uiuc","oai_identifier":"oai:www.ideals.illinois.edu:2142/110613"},"canonical_url":"https://search.dev.ndltd.org/etd/uiuc/oai:www.ideals.illinois.edu:2142/110613","repository":{"repo_id":"uiuc","name":"University of Illinois - Urbana-Champaign","base_url":"https://www.ideals.illinois.edu/oai-pmh"},"display":{"title":"Establishment of hedgehog pathway overexpression in osteosarcoma cell lines leading to an anti-apoptotic genotype which can be inhibited by the common anti-fungal and hedgehog pathway inhibitor, itraconazole","abstract":"Osteosarcoma (OS) is the most common primary bone cancer in dogs, yet therapies for pets with metastatic OS remain clinically ineffective. With the advent of precision medicine, strong scientific and clinical impetus exists to further investigate druggable molecular perturbations that might contribute to canine OS pathology. Dysregulated activity of the hedgehog (HH) pathway has been identified in diverse cancers in people and animals and leads to overexpression of anti-apoptotic proteins including Bcl-2 and c-FLIP. This produces an anti-apoptotic genotype by influencing both the intrinsic and extrinsic arms of the apoptotic pathway. Itraconazole is an antifungal agent that has been found to inhibit Smoothened (SMO), a crucial G protein-coupled receptor located on the cell membrane and becomes activated on the primary cilium, which allows initiation of HH pathway signaling. We hypothesize that components of the HH pathway are overexpressed in canine OS cell lines with concurrent downstream anti-apoptotic factor overexpression relative to non-malignant osteoblasts. Additionally, itraconazole would inhibit HH pathway signaling by promoting SMO relocation off the primary cilium. RNA transcript and protein expressions of SMO, Bcl-2 and c-FLIP were characterized in three canine OS cell lines and normal canine osteoblast cultures. The IC50 concentrations of itraconazole in OS cell lines were determined, and itraconazole’s effects on the HH pathway signaling partners were evaluated at RNA and protein levels. Confocal microscopy was utilized to confirm the modulation of protein levels after treatment with itraconazole. In addition, the effect of the combinations of itraconazole and commonly used cytotoxic agents, doxorubicin and carboplatin, were explored with regard to cell death. This data was used to assess the tolerability of itraconazole in combination with these chemotherapeutics in a murine model which was then used to explore the effects of itraconazole with or without cytotoxic agents on a metastatic osteosarcoma model. OS cell lines overexpress SMO, Bcl-2, and c-FLIP relative to normal osteoblasts. The IC50 of itraconazole in OS cells ranged from 490-790 nM. Itraconazole effectively perturbs protein expressions of the HH signaling pathway and downstream targets. The combination of itraconazole with carboplatin and itraconazole with doxorubicin was found to be synergistic compared to agents alone with regard to cell death. The combination of cytotoxin and itraconazole was found to be tolerable in mice with no cumulative toxicity. SMO and Bcl-2 are overexpressed in OS cells and itraconazole can disrupt the HH signaling pathway at biologically relevant concentrations, warranting further investigation of itraconazole as adjuvant therapy for OS.","abstract_html":"Osteosarcoma (OS) is the most common primary bone cancer in dogs, yet therapies for pets with metastatic OS remain clinically ineffective. With the advent of precision medicine, strong scientific and clinical impetus exists to further investigate druggable molecular perturbations that might contribute to canine OS pathology. Dysregulated activity of the hedgehog (HH) pathway has been identified in diverse cancers in people and animals and leads to overexpression of anti-apoptotic proteins including Bcl-2 and c-FLIP. This produces an anti-apoptotic genotype by influencing both the intrinsic and extrinsic arms of the apoptotic pathway. Itraconazole is an antifungal agent that has been found to inhibit Smoothened (SMO), a crucial G protein-coupled receptor located on the cell membrane and becomes activated on the primary cilium, which allows initiation of HH pathway signaling. We hypothesize that components of the HH pathway are overexpressed in canine OS cell lines with concurrent downstream anti-apoptotic factor overexpression relative to non-malignant osteoblasts. Additionally, itraconazole would inhibit HH pathway signaling by promoting SMO relocation off the primary cilium. RNA transcript and protein expressions of SMO, Bcl-2 and c-FLIP were characterized in three canine OS cell lines and normal canine osteoblast cultures. The IC50 concentrations of itraconazole in OS cell lines were determined, and itraconazole’s effects on the HH pathway signaling partners were evaluated at RNA and protein levels. Confocal microscopy was utilized to confirm the modulation of protein levels after treatment with itraconazole. In addition, the effect of the combinations of itraconazole and commonly used cytotoxic agents, doxorubicin and carboplatin, were explored with regard to cell death. This data was used to assess the tolerability of itraconazole in combination with these chemotherapeutics in a murine model which was then used to explore the effects of itraconazole with or without cytotoxic agents on a metastatic osteosarcoma model. OS cell lines overexpress SMO, Bcl-2, and c-FLIP relative to normal osteoblasts. The IC50 of itraconazole in OS cells ranged from 490-790 nM. Itraconazole effectively perturbs protein expressions of the HH signaling pathway and downstream targets. The combination of itraconazole with carboplatin and itraconazole with doxorubicin was found to be synergistic compared to agents alone with regard to cell death. The combination of cytotoxin and itraconazole was found to be tolerable in mice with no cumulative toxicity. SMO and Bcl-2 are overexpressed in OS cells and itraconazole can disrupt the HH signaling pathway at biologically relevant concentrations, warranting further investigation of itraconazole as adjuvant therapy for OS.","abstract_has_math":false,"creators":["Connell, Dana Rachelle"],"institution":"University of Illinois at Urbana-Champaign","degree_name":"M.S.","degree_level":"Thesis","degree_discipline":"Veterinary Clinical Medicine","degree_department":null,"school":null,"contributors":["Fan, Timothy M","Foss, Kari","Barger, Anne"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2021,"date_issued":"2021-09-17T02:34:08Z","date_published":"2021-09-17T02:34:08Z","updated_at":"2026-07-22T22:24:52Z","subjects":["Osteosarcoma","canine","itraconazole","hedgehog","smoothened"],"languages":["en"],"rights":["Copyright 2021 Dana Connell"],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/2142/110613","outbound_label":"Handle","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Fan, Timothy M","Foss, Kari","Barger, Anne"]},{"key":"dc:creator","label":"Author","values":["Connell, Dana Rachelle"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2021-09-17T02:34:08Z","2023-09-17T02:34:57Z","2020-11-18","2021-05"]},{"key":"dc:type","label":"Dc Type","values":["text","Thesis"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Veterinary Clinical Medicine"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Thesis"]},{"key":"thesis:degree_name","label":"Degree Name","values":["M.S."]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["University of Illinois at Urbana-Champaign"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Osteosarcoma","canine","itraconazole","hedgehog","smoothened"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["en"]},{"key":"dc:rights","label":"Dc Rights","values":["Copyright 2021 Dana Connell"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["http://hdl.handle.net/2142/110613"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Osteosarcoma (OS) is the most common primary bone cancer in dogs, yet therapies for pets with metastatic OS remain clinically ineffective. With the advent of precision medicine, strong scientific and clinical impetus exists to further investigate druggable molecular perturbations that might contribute to canine OS pathology. Dysregulated activity of the hedgehog (HH) pathway has been identified in diverse cancers in people and animals and leads to overexpression of anti-apoptotic proteins including Bcl-2 and c-FLIP. This produces an anti-apoptotic genotype by influencing both the intrinsic and extrinsic arms of the apoptotic pathway. Itraconazole is an antifungal agent that has been found to inhibit Smoothened (SMO), a crucial G protein-coupled receptor located on the cell membrane and becomes activated on the primary cilium, which allows initiation of HH pathway signaling. We hypothesize that components of the HH pathway are overexpressed in canine OS cell lines with concurrent downstream anti-apoptotic factor overexpression relative to non-malignant osteoblasts. Additionally, itraconazole would inhibit HH pathway signaling by promoting SMO relocation off the primary cilium. RNA transcript and protein expressions of SMO, Bcl-2 and c-FLIP were characterized in three canine OS cell lines and normal canine osteoblast cultures. The IC50 concentrations of itraconazole in OS cell lines were determined, and itraconazole’s effects on the HH pathway signaling partners were evaluated at RNA and protein levels. Confocal microscopy was utilized to confirm the modulation of protein levels after treatment with itraconazole. In addition, the effect of the combinations of itraconazole and commonly used cytotoxic agents, doxorubicin and carboplatin, were explored with regard to cell death. This data was used to assess the tolerability of itraconazole in combination with these chemotherapeutics in a murine model which was then used to explore the effects of itraconazole with or without cytotoxic agents on a metastatic osteosarcoma model. OS cell lines overexpress SMO, Bcl-2, and c-FLIP relative to normal osteoblasts. The IC50 of itraconazole in OS cells ranged from 490-790 nM. Itraconazole effectively perturbs protein expressions of the HH signaling pathway and downstream targets. The combination of itraconazole with carboplatin and itraconazole with doxorubicin was found to be synergistic compared to agents alone with regard to cell death. The combination of cytotoxin and itraconazole was found to be tolerable in mice with no cumulative toxicity. SMO and Bcl-2 are overexpressed in OS cells and itraconazole can disrupt the HH signaling pathway at biologically relevant concentrations, warranting further investigation of itraconazole as adjuvant therapy for OS.","Submission published under a 24 month embargo labeled 'U of I Access', the embargo will last until 2023-05-01","The student, Dana Connell, accepted the attached license on 2020-11-02 at 19:08.","The student, Dana Connell, submitted this Thesis for approval on 2020-11-02 at 20:00.","This Thesis was approved for publication on 2020-11-18 at 12:01.","DSpace SAF Submission Ingestion Package generated from Vireo submission #15854 on 2021-09-16 at 17:01:23","Made available in DSpace on 2021-09-17T02:34:08Z (GMT). No. of bitstreams: 2 CONNELL-THESIS-2021.pdf: 19956003 bytes, checksum: 064479b56f45d3d97352ed353da6f636 (MD5) LICENSE.txt: 4209 bytes, checksum: 2123bcc867e8b44075982001fa179353 (MD5) Previous issue date: 2020-11-18","Embargo set by: Seth Robbins for item 118456 Lift date: 2023-09-17T02:34:57Z Reason: Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","U of I Only"]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dc:title","label":"Title","values":["Establishment of hedgehog pathway overexpression in osteosarcoma cell lines leading to an anti-apoptotic genotype which can be inhibited by the common anti-fungal and hedgehog pathway inhibitor, itraconazole"]}]}],"canonical_facts":{"dc:contributor":["Fan, Timothy M","Foss, Kari","Barger, Anne"],"dc:creator":["Connell, Dana Rachelle"],"dc:date":["2021-09-17T02:34:08Z","2023-09-17T02:34:57Z","2020-11-18","2021-05"],"dc:description":["Osteosarcoma (OS) is the most common primary bone cancer in dogs, yet therapies for pets with metastatic OS remain clinically ineffective. With the advent of precision medicine, strong scientific and clinical impetus exists to further investigate druggable molecular perturbations that might contribute to canine OS pathology. Dysregulated activity of the hedgehog (HH) pathway has been identified in diverse cancers in people and animals and leads to overexpression of anti-apoptotic proteins including Bcl-2 and c-FLIP. This produces an anti-apoptotic genotype by influencing both the intrinsic and extrinsic arms of the apoptotic pathway. Itraconazole is an antifungal agent that has been found to inhibit Smoothened (SMO), a crucial G protein-coupled receptor located on the cell membrane and becomes activated on the primary cilium, which allows initiation of HH pathway signaling. We hypothesize that components of the HH pathway are overexpressed in canine OS cell lines with concurrent downstream anti-apoptotic factor overexpression relative to non-malignant osteoblasts. Additionally, itraconazole would inhibit HH pathway signaling by promoting SMO relocation off the primary cilium. RNA transcript and protein expressions of SMO, Bcl-2 and c-FLIP were characterized in three canine OS cell lines and normal canine osteoblast cultures. The IC50 concentrations of itraconazole in OS cell lines were determined, and itraconazole’s effects on the HH pathway signaling partners were evaluated at RNA and protein levels. Confocal microscopy was utilized to confirm the modulation of protein levels after treatment with itraconazole. In addition, the effect of the combinations of itraconazole and commonly used cytotoxic agents, doxorubicin and carboplatin, were explored with regard to cell death. This data was used to assess the tolerability of itraconazole in combination with these chemotherapeutics in a murine model which was then used to explore the effects of itraconazole with or without cytotoxic agents on a metastatic osteosarcoma model. OS cell lines overexpress SMO, Bcl-2, and c-FLIP relative to normal osteoblasts. The IC50 of itraconazole in OS cells ranged from 490-790 nM. Itraconazole effectively perturbs protein expressions of the HH signaling pathway and downstream targets. The combination of itraconazole with carboplatin and itraconazole with doxorubicin was found to be synergistic compared to agents alone with regard to cell death. The combination of cytotoxin and itraconazole was found to be tolerable in mice with no cumulative toxicity. SMO and Bcl-2 are overexpressed in OS cells and itraconazole can disrupt the HH signaling pathway at biologically relevant concentrations, warranting further investigation of itraconazole as adjuvant therapy for OS.","Submission published under a 24 month embargo labeled 'U of I Access', the embargo will last until 2023-05-01","The student, Dana Connell, accepted the attached license on 2020-11-02 at 19:08.","The student, Dana Connell, submitted this Thesis for approval on 2020-11-02 at 20:00.","This Thesis was approved for publication on 2020-11-18 at 12:01.","DSpace SAF Submission Ingestion Package generated from Vireo submission #15854 on 2021-09-16 at 17:01:23","Made available in DSpace on 2021-09-17T02:34:08Z (GMT). No. of bitstreams: 2 CONNELL-THESIS-2021.pdf: 19956003 bytes, checksum: 064479b56f45d3d97352ed353da6f636 (MD5) LICENSE.txt: 4209 bytes, checksum: 2123bcc867e8b44075982001fa179353 (MD5) Previous issue date: 2020-11-18","Embargo set by: Seth Robbins for item 118456 Lift date: 2023-09-17T02:34:57Z Reason: Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","U of I Only"],"dc:format":["application/pdf"],"dc:identifier":["http://hdl.handle.net/2142/110613"],"dc:language":["en"],"dc:rights":["Copyright 2021 Dana Connell"],"dc:subject":["Osteosarcoma","canine","itraconazole","hedgehog","smoothened"],"dc:title":["Establishment of hedgehog pathway overexpression in osteosarcoma cell lines leading to an anti-apoptotic genotype which can be inhibited by the common anti-fungal and hedgehog pathway inhibitor, itraconazole"],"dc:type":["text","Thesis"],"thesis:degree_discipline":["Veterinary Clinical Medicine"],"thesis:degree_level":["Thesis"],"thesis:degree_name":["M.S."],"thesis:institution_name":["University of Illinois at Urbana-Champaign"]},"updated_at":"2026-07-22T22:24:52Z"}